A recent study has highlighted the benefits of lowering systolic blood pressure (SBP) to below 120mmHg in diabetic patients. Compared to the standard treatment goal of 140mmHg, this approach can reduce cardiovascular disease risk by 21%. These findings were unveiled at the American Heart Association (AHA) Scientific Sessions and have drawn significant attention from the medical community.
The Importance of Blood Pressure Management in Diabetes
Hypertension affects approximately 30–50% of diabetic patients and is a major risk factor for stroke and heart attack. Studies show that high blood pressure can increase stroke risk by up to five times, making blood pressure control a critical focus in diabetes management.
Current guidelines by the Korean Diabetes Association recommend blood pressure targets of 140/90mmHg for general patients and 130/80mmHg for high-risk groups. However, this new study suggests that 120mmHg could be a more effective target for better outcomes.
Overview of the BPROAD Study
Led by Professor Guang Ning from Ruijin Hospital in Shanghai, the BPROAD study involved over 12,000 adults with type 2 diabetes across 145 medical institutions in China. The study was conducted over five years, comparing two groups:
- Intensive Treatment Group: SBP target of 120mmHg
- Standard Treatment Group: SBP target of 140mmHg
Key Findings
The intensive treatment group maintained an average SBP of 120.6mmHg, while the standard treatment group averaged 132.1mmHg. This difference resulted in a 21% lower risk of major cardiovascular events in the intensive group.
Side Effects and Safety
Although the incidence of serious side effects was similar between the two groups, the intensive treatment group experienced slightly higher rates of symptomatic hypotension and hyperkalemia. These effects were deemed manageable within clinical settings.
Expert Opinions
Professor Guang Ning stated, “Intensive blood pressure management significantly reduces cardiovascular risks and aligns with findings from studies on non-diabetic hypertensive patients. We hope these results influence future clinical guidelines.”
Lowering the blood pressure target to 120mmHg represents a significant step forward in diabetes management. By reducing cardiovascular risk and improving patient outcomes, this approach could redefine clinical practices and benefit millions of patients worldwide.
